A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

被引：0

作者：

Yoon, Sang Eun ^{[1
]}

Jung, Sung-Hoon ^{[2
]}

Lee, Gyeong Won ^{[3
]}

Min, Chang-Ki ^{[4
]}

Byun, Ja Min ^{[5
]}

Kwak, Jae-Yong ^{[6
]}

Lee, Myung-Won ^{[7
]}

Lee, Ho Sup ^{[8
]}

Kim, Seok Jin ^{[9
]}

Kim, Kihyun ^{[1
,10
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Samsung Med Ctr,Dept Med, Seoul, South Korea

[2] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Hwasun, South Korea

[3] Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju, South Korea

[4] Catholic Univ Korea, Catholic Hematol Hosp, Seoul St Marys Hosp, Dept Hematol,Coll Med, Seoul, South Korea

[5] Seoul Natl Univ, Seoul, South Korea

[6] Chonbuk Natl Univ, Med Sch, Jeonju, South Korea

[7] Chungnam Natl Univ, Coll Med, Dept Internal Med, Daejeon, South Korea

[8] Kosin Univ Gospel Hosp, Dept Internal Med, Busan, South Korea

[9] Samsung Med Ctr, Seoul, South Korea

[10] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-198947

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7045 / 7046

页数：2

共 50 条

[21] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
Voorhees, Peter M.
Rodriguez, Cesar
Reeves, Brandi
Nathwani, Nitya
Costa, Luciano J.
Lutska, Yana
Bobba, Padma
Hoehn, Daniela
Pei, Huiling
Ukropec, Jon
Qi, Ming
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136
[22] Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
Saj, Fen
Nisha, Yadav
Ganesan, Prasanth
Kayal, Smita
Kar, Rakhee
Halanaik, Dhanapathi
Dubashi, Biswajit
BLOOD CANCER JOURNAL, 2023, 13 (01)
[23] Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study
Fen Saj
Yadav Nisha
Prasanth Ganesan
Smita Kayal
Rakhee Kar
Dhanapathi Halanaik
Biswajit Dubashi
Blood Cancer Journal, 13
[24] Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study
Anderson, K. C.
Weller, E.
Lonial, S.
Jakubowiak, A. J.
Jagannath, S.
Raje, N. S.
Avigan, D.
Knight, R. D.
Esseltine, D.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[25] Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
Bhutani, Manisha
House, Monika
He, Jiaxian
Atrash, Shebli
Foureau, David M.
Paul, Barry
Friend, Reed
Symanowski, James T.
Norek, Sarah
Begic, Xhevahire
Acampora, Donna
Farmer, Katherine K.
Syfert, Carrie Ann
Pineda-Roman, Mauricio
Voorhees, Peter
Usmani, Saad Z.
BLOOD, 2020, 136
[26] Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study
Richardson, Paul
Lonial, Sagar
Jakubowiak, Andrzej
Jagannath, Sundar
Raje, Noopur S.
Avigan, David
Ghobrial, Irene M.
Schlossman, Robert L.
Mazumder, Amitabha
Munshi, Nikhil C.
Vesole, David H.
Joyce, Robin
Doss, Deborah
Warren, Diane L.
Hayes, Stephen W.
Kaster, Sarah
Delaney, Carol
Lauria, Marisa
Mitsiades, Constantine
Hideshima, Teru
Knight, Robert D.
Esseltine, Dixie-Lee
Anderson, Kenneth C.
BLOOD, 2008, 112 (11) : 41 - 41
[27] A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
Sonneveld, Pieter
Dimopoulos, Meletios A.
Boccadoro, Mario
Quach, Hang
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
van de Donk, Niels W. C. J.
Katodritou, Eirini
Schjesvold, Fredrik
Balari, Anna Sureda
Rosinol, Laura
Delforge, Michel
Roeloffzen, Wilfried
Silzle, Tobias
Vangsted, Annette
Einsele, Hermann
Spencer, Andrew
Hajek, Roman
Jurczyszyn, Artur
Lonergan, Sarah
Ahmadi, Tahamtan
Liu, Yanfang
Wang, Jianping
Vieyra, Diego
van Brummelen, Emilie M. J.
Vanquickelberghe, Veronique
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Rodriguez-Otero, Paula
Blade, Joan
Moreau, Philippe
FUTURE ONCOLOGY, 2024, 20 (38) : 3043 - 3063
[28] Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
Sborov, Douglas W.
Baljevic, Muhamed
Reeves, Brandi
Laubach, Jacob
Efebera, Yvonne A.
Rodriguez, Cesar
Costa, Luciano J.
Chari, Ajai
Silbermann, Rebecca
Holstein, Sarah A.
Anderson, Larry D., Jr.
Kaufman, Jonathan L.
Shah, Nina
Pei, Huiling
Patel, Sharmila
Cortoos, Annelore
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Voorhees, Peter M.
Richardson, Paul G.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (03) : 355 - 365
[29] Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
Rosinol, Laura
Hebraud, Benjamin
Oriol, Albert
Colin, Anne-Laurene
Tamayo, Rafael Rios
Hulin, Cyrille
Blanchard, Maria Jesus
Caillot, Denis
Sureda, Anna
Hernandez, Miguel Teodoro
Arnulf, Bertrand
Mateos, Maria-Victoria
Macro, Margaret
San-Miguel, Jesus
Belhadj, Karim
Lahuerta, Juan Jose
Garelik, M. Brigid
Blade, Joan
Moreau, Philippe
FRONTIERS IN ONCOLOGY, 2023, 13
[30] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
Suzuki, Kazuhito
Tsukada, Nobuhiro
Nishimura, Noriko
Nagata, Yasuyuki
Okazuka, Kiyoshi
Mishima, Yuko
Yokoyama, Masahiro
Nishiwaki, Kaichi
Ishida, Tadao
Yano, Shingo
Terui, Yasuhito
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 103 - 111

← 1 2 3 4 5 →